App-Quantinova.ai

Serum protein predictors of long term survival from combined ipilimumab and nivolumab therapy in metastatic melanoma patients.

Krisztian Homicsko - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

A multicenter retrospective analysis of nivolumab in advanced melanoma during the French Temporary Authorization Use.

Sandrine Monestier - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Incidence and characteristics of adrenal insufficiency following immune checkpoint inhibitor therapy for melanoma.

Logan Rhea - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Treatment outcomes of cutaneous adverse events to immune checkpoint inhibitors.

Jennifer Wu - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Activity of single-agent PD-1 inhibitor (PD-1i) therapy in advanced sarcoma: A single-center retrospective analysis.

Dionisia Marie Quiroga - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Clinical experience with combination chemo-/immunotherapy using trabectedin and nivolumab for advanced soft tissue sarcoma.

Sant P. Chawla - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

High pretreatment neutrophil-to-lymphocyte ratio (NLR) and its reactive increase as better predictors of poor clinical outcomes compared to tumor mutation burden (TMB) in solid tumor patients treated with immune checkpoint inhibitors (ICI).

Vaia Florou - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Neutrophil-to-lymphocyte ratio (NLR) conversion during checkpoint inhibitors therapy as a early prognostic factor.

Jefferson Rios Pimenta - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Nivolumab

Tetrahydrouridine/decitabine/5-azacytidine for non-cytotoxic epigenetic-immunotherapy of NSCLC in vivo.

Kai Kang - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Monitoring peripheral blood PD-1+CD8+ T cells to predict response to anti-PD-1 therapy in solid tumors.

Kyung Hwan Kim - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Inflammatory biomarkers in HIV-infected veterans with non-small cell lung cancer receiving antiPD-1 immunotherapy.

Elaine Chang - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Association of baseline and longitudinal low neutrophil-lymphocyte ratio (NLR) and high lymphocyte counts (LCs) with progression-free survival (PFS) and overall survival (OS) in real world advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with nivolumab (nivo) or pembrolizumab (pembro).

Stephanie Labomascus - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Correlation between the TTF-1 expression and immune-related thyroid dysfunction and efficacy of anti-PD1 treatment in non-small cell lung cancer.

Junji Koyama - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Novel antiangiogenic drugs, immune checkpoint inhibitors, and chemotherapy in patients with aNSCLC who have aggressive disease: A systematic review.

Katherine B. Winfree - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Correlation of PBMC CD62Llow CD4+ T cells with irILD after nivolumab therapy.

Ou Yamaguchi - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Clinical outcomes of African-American patients with advanced or metastatic non-small cell lung cancer on nivolumab in a single community based cancer center.

Andrew Chua Tiu - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

A multicenter observational study of effectiveness and safety of nivolumab in non-small cell lung cancer in real clinical practice.

Juan Francisco Marin Pozo - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Long term effect of nivolumab in patients with non-small cell lung cancer.

Mette Sprauten - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Comparison of immunotherapy response rates in non-small cell lung cancer following platinum-based chemotherapy.

Taylor Mai Weis - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Correlation of survival of NSCLC patients given nivolumab with treatment related-eosinophilia, autoimmunity and previous bevacizumab containing regimens.

Rocco Giannicola - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Filters

2342 Abstracts